The ASX 50 index is home to 50 of the largest listed companies on the Australian share market.
While there are a number of quality options on offer in the index, two that could be in the buy zone are listed below.
Here’s what you need to know about these ASX 50 shares:
CSL Limited (ASX: CSL)
The first ASX 50 share to look at is CSL. It is one of the world’s leading biotherapeutics companies.
It has been a very positive performer over the last decade. This has been driven by successful acquisitions, its high level of investment in R&D activities, a growing plasma collection network, and its leading therapies and vaccines.
In respect to the latter, CSL’s portfolio includes lucrative and life-saving products such as Privigen, Hizentra, Idelvion, and Afstyla. But it certainly isn’t resting on its laurels. This year the company will spend approximately US$1 billion again on R&D. This is to ensure it has a pipeline of lucrative products to drive future growth.
While the pandemic has hit plasma collections and could lead to elevated costs in the near term, this headwind is only expected to be temporary.
One broker that remains positive on the company is Morgans. It currently has an add rating and $324.40 price target.
SEEK Limited (ASX: SEK)
Another ASX 50 share to look at is SEEK. It is the leading job listings company in the ANZ region and has a number of growing businesses around the globe.
During FY 2021, the company returned to form and reported a 58% jump in net profit after tax excluding significant items to $141 million.
This was underpinned by record ad volumes in the second half of the year amid easing COVID-19 restrictions. This ultimately led to SEEK reporting an average of 40 million monthly site visits during the year, which represents 10% growth on pre-COVID-19 levels.
According to a note out of Macquarie, its analysts are confident this positive form will continue. Particularly given how unemployment levels are tipped to fall materially following the pandemic, which should support job ad volumes.
Macquarie has an outperform rating and $37.00 price target on the company’s shares.